Literature DB >> 28900677

Tim-3, Lag-3, and TIGIT.

Nicole Joller1, Vijay K Kuchroo2.   

Abstract

Co-inhibitory receptors play a key role in regulating T cell responses and maintaining immune homeostasis. Their inhibitory function prevents autoimmune responses but also restricts the ability of T cells to mount effective immune responses against tumors or persistent pathogens. T cells express a module of co-inhibitory receptors, which display great diversity in expression, structure, and function. Here, we focus on the co-inhibitory receptors Tim-3, Lag-3, and TIGIT and how they regulate T cell function, maintenance of self-tolerance, their role in regulating ongoing T cell responses at peripheral tissues, and their synergistic effects in regulating autoimmunity and antitumor responses.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28900677      PMCID: PMC5902028          DOI: 10.1007/82_2017_62

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  135 in total

1.  Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.

Authors:  Lishomwa C Ndhlovu; Sandra Lopez-Vergès; Jason D Barbour; R Brad Jones; Aashish R Jha; Brian R Long; Eric C Schoeffler; Tsuyoshi Fujita; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

2.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

3.  Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma.

Authors:  Liyun Xu; Yanyan Huang; Linlin Tan; Wei Yu; Dongdong Chen; ChangChang Lu; Jianying He; Guoqing Wu; Xiaoguang Liu; Yongkui Zhang
Journal:  Int Immunopharmacol       Date:  2015-10-01       Impact factor: 4.932

4.  Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3.

Authors:  Maria Bettini; Andrea L Szymczak-Workman; Karen Forbes; Ashley H Castellaw; Mark Selby; Xiaoyu Pan; Charles G Drake; Alan J Korman; Dario A A Vignali
Journal:  J Immunol       Date:  2011-08-26       Impact factor: 5.422

5.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

Authors:  Shin Foong Ngiow; Bianca von Scheidt; Hisaya Akiba; Hideo Yagita; Michele W L Teng; Mark J Smyth
Journal:  Cancer Res       Date:  2011-03-23       Impact factor: 12.701

6.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

7.  T-bet, a Th1 transcription factor regulates the expression of Tim-3.

Authors:  Ana C Anderson; Graham M Lord; Valerie Dardalhon; David H Lee; Catherine A Sabatos-Peyton; Laurie H Glimcher; Vijay K Kuchroo
Journal:  Eur J Immunol       Date:  2010-03       Impact factor: 5.532

8.  Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.

Authors:  Helge Frebel; Veronika Nindl; Reto A Schuepbach; Thomas Braunschweiler; Kirsten Richter; Johannes Vogel; Carsten A Wagner; Dominique Loffing-Cueni; Michael Kurrer; Burkhard Ludewig; Annette Oxenius
Journal:  J Exp Med       Date:  2012-12-10       Impact factor: 14.307

9.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.

Authors:  R Brad Jones; Lishomwa C Ndhlovu; Jason D Barbour; Prameet M Sheth; Aashish R Jha; Brian R Long; Jessica C Wong; Malathy Satkunarajah; Marc Schweneker; Joan M Chapman; Gabor Gyenes; Bahareh Vali; Martin D Hyrcza; Feng Yun Yue; Colin Kovacs; Aref Sassi; Mona Loutfy; Roberta Halpenny; Desmond Persad; Gerald Spotts; Frederick M Hecht; Tae-Wook Chun; Joseph M McCune; Rupert Kaul; James M Rini; Douglas F Nixon; Mario A Ostrowski
Journal:  J Exp Med       Date:  2008-11-10       Impact factor: 14.307

10.  Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.

Authors:  Cristina Bottino; Roberta Castriconi; Daniela Pende; Paola Rivera; Marina Nanni; Barbara Carnemolla; Claudia Cantoni; Jessica Grassi; Stefania Marcenaro; Nicolas Reymond; Massimo Vitale; Lorenzo Moretta; Marc Lopez; Alessandro Moretta
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  40 in total

1.  Fewer LAG-3+ T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes.

Authors:  Britta E Jones; Megan D Maerz; Henry T Bahnson; Ashwin Somasundaram; Lucas H McCarthy; Cate Speake; Jane H Buckner
Journal:  J Immunol       Date:  2022-01-12       Impact factor: 5.422

2.  Resistance to Immunotherapy: Mechanisms and Means for Overcoming.

Authors:  Mohamad A Salkeni; John Y Shin; James L Gulley
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Exhausted PD-1+ TOX+ CD8+ T Cells Arise Only in Long-Term Experimental Trypanosoma cruzi Infection.

Authors:  Rosa Isela Gálvez; Thomas Jacobs
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

Review 4.  Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.

Authors:  Peng Ding; Zhiqiang Ma; Dong Liu; Minghong Pan; Huizi Li; Yingtong Feng; Yimeng Zhang; Changjian Shao; Menglong Jiang; Di Lu; Jing Han; Jinliang Wang; Xiaolong Yan
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

Review 5.  PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.

Authors:  Tianrui Yang; Ziren Kong; Wenbin Ma
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

6.  A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1.

Authors:  Xin Zhang; Haipeng Zhu; Xu Zheng; Yunjie Jiao; Lulu Ning; En-Min Zhou; Yang Mu
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

Review 7.  Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future.

Authors:  Zhongquan Cheng; Yang Du; Leyi Yu; Zhu Yuan; Jie Tian
Journal:  Mol Imaging Biol       Date:  2022-01-31       Impact factor: 3.488

8.  Identification and Validation of an 11-Ferroptosis Related Gene Signature and Its Correlation With Immune Checkpoint Molecules in Glioma.

Authors:  Zhuohui Chen; Tong Wu; Zhouyi Yan; Mengqi Zhang
Journal:  Front Cell Dev Biol       Date:  2021-06-23

Review 9.  CAR T cells: Building on the CD19 paradigm.

Authors:  Anat Globerson Levin; Isabelle Rivière; Zelig Eshhar; Michel Sadelain
Journal:  Eur J Immunol       Date:  2021-08-02       Impact factor: 6.688

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.